(ACRI-B) Acrinova Series - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0015660030
ACRI-B: Residential, Commercial, Industrial, Properties
Acrinova AB (publ) is a Swedish real estate company specializing in the ownership, development, and management of a diversified property portfolio. The companys assets span residential, retail, and industrial properties, including apartments, commercial premises, offices, and warehouses. Acrinova actively manages its portfolio to optimize returns and align with market demand. Incorporated in 2014, the company is headquartered in Malmö, a key regional hub in southern Sweden. Its strategic focus includes maintaining a balanced portfolio across different property types to mitigate risks and capitalize on growth opportunities in the Swedish real estate market. Web URL: https://www.acrinova.se
Based on the provided data, Acrinova AB Series B (ST:ACRI-B) shows a mixed outlook. From a technical perspective, the stock is trading above its SMA 20 and SMA 50, indicating short-term bullish momentum. However, the SMA 200 remains below the current price, suggesting a cautious long-term trend. The ATR of 0.46 reflects moderate volatility. On the fundamental side, the P/B ratio of 0.80 indicates undervaluation relative to book value, while the P/S ratio of 5.09 points to a premium valuation based on sales. The RoE of 3.78% is relatively low, signaling moderate profitability. Overall, the stock may see near-term upside driven by momentum but faces headwinds from elevated valuations and low earnings efficiency.
Additional Sources for ACRI-B Stock
ACRI-B Stock Overview
Market Cap in USD | 82m |
Sector | Real Estate |
Industry | Real Estate - Diversified |
GiC Sub-Industry | Real Estate Operating Companies |
IPO / Inception |
ACRI-B Stock Ratings
Growth Rating | 7.55 |
Fundamental | 21.4 |
Dividend Rating | 38.9 |
Rel. Strength | 18.6 |
Analysts | - |
Fair Price Momentum | 12.40 SEK |
Fair Price DCF | 7.15 SEK |
ACRI-B Dividends
Dividend Yield 12m | 5.45% |
Yield on Cost 5y | 5.60% |
Annual Growth 5y | -6.29% |
Payout Consistency | 84.5% |
ACRI-B Growth Ratios
Growth Correlation 3m | 87% |
Growth Correlation 12m | 53.5% |
Growth Correlation 5y | -32.1% |
CAGR 5y | 3.56% |
CAGR/Max DD 5y | 0.07 |
Sharpe Ratio 12m | -0.09 |
Alpha | 41.22 |
Beta | -0.448 |
Volatility | 39.00% |
Current Volume | 4.8k |
Average Volume 20d | 11.1k |
As of May 09, 2025, the stock is trading at SEK 11.35 with a total of 4,792 shares traded.
Over the past week, the price has changed by +4.53%, over one month by +7.36%, over three months by +35.12% and over the past year by +36.97%.
Neither. Based on ValueRay Fundamental Analyses, Acrinova Series is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 21.40 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACRI-B as of May 2025 is 12.40. This means that ACRI-B is currently overvalued and has a potential downside of 9.25%.
Acrinova Series has no consensus analysts rating.
According to ValueRays Forecast Model, ACRI-B Acrinova Series will be worth about 13.4 in May 2026. The stock is currently trading at 11.35. This means that the stock has a potential upside of +17.97%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 13.4 | 18% |